S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
66,000% upside on tiny biotech? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
66,000% upside on tiny biotech? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
66,000% upside on tiny biotech? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
3 Drone Stocks That Can Lift Your Portfolio Higher
66,000% upside on tiny biotech? (Ad)
3 Quality Stocks On Track for Significant Dividend Increases
International Paper's 5% Yield Offers Big Value
66,000% upside on tiny biotech? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
66,000% upside on tiny biotech? (Ad)
This Is One of the Top-Rated and Most-Upgraded Stocks
5 Economic Trends That Will Drive The Market In Q4
NASDAQ:PRQR

ProQR Therapeutics (PRQR) Stock Forecast, Price & News

$1.44
+0.19 (+15.20%)
(As of 10/3/2023 ET)
Compare
Today's Range
$1.18
▼
$1.58
50-Day Range
$1.25
▼
$1.63
52-Week Range
$0.79
▼
$3.85
Volume
1.25 million shs
Average Volume
636,273 shs
Market Capitalization
$116.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.88
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

ProQR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
169.7% Upside
$3.88 Price Target
Short Interest
Healthy
1.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.92mentions of ProQR Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.28) to ($0.39) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

797th out of 967 stocks

Pharmaceutical Preparations Industry

362nd out of 434 stocks

See Top Rated MarketRank™ Stocks Here

PRQR stock logo

About ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

PRQR Price History

PRQR Stock News Headlines

October 3, 2023 | americanbankingnews.com
ProQR Therapeutics (NASDAQ:PRQR) vs. Enveric Biosciences (NASDAQ:ENVB) Financial Contrast
September 28, 2023 | finance.yahoo.com
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
October 4, 2023 | Stansberry Research (Ad)
Is NVIDIA Leading a "Magnificent Seven Bubble"?
The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks. 
September 27, 2023 | finance.yahoo.com
ProQR Therapeutics Provides Update on Ophthalmic Assets
September 7, 2023 | finance.yahoo.com
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
August 8, 2023 | finance.yahoo.com
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutions
August 4, 2023 | msn.com
Chardan Capital Reiterates ProQR Therapeutics N.V (PRQR) Neutral Recommendation
August 4, 2023 | markets.businessinsider.com
4 Analysts Have This to Say About ProQR Therapeutics
October 4, 2023 | Stansberry Research (Ad)
Is NVIDIA Leading a "Magnificent Seven Bubble"?
The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks. 
August 3, 2023 | uk.finance.yahoo.com
ProQR Announces Second Quarter 2023 Operating and Financial Results
August 2, 2023 | technews.tmcnet.com
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets
August 1, 2023 | finance.yahoo.com
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
July 18, 2023 | finance.yahoo.com
PRQR Oct 2023 7.500 call
June 28, 2023 | stocknews.com
2 Biotech Stocks to Buy, 1 to Sell Now
June 28, 2023 | finance.yahoo.com
ProQR Therapeutics' (NASDAQ:PRQR) investors will be pleased with their impressive 109% return over the last year
May 23, 2023 | markets.businessinsider.com
Chardan Capital Remains a Hold on ProQR (PRQR)
May 18, 2023 | finance.yahoo.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability
May 17, 2023 | msn.com
HC Wainwright & Co. Reiterates ProQR Therapeutics N.V (PRQR) Buy Recommendation
May 17, 2023 | msn.com
JMP Securities Reiterates ProQR Therapeutics N.V (PRQR) Market Outperform Recommendation
May 17, 2023 | msn.com
Analyst Ratings for ProQR Therapeutics
May 17, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for ProQR (PRQR)
May 16, 2023 | msn.com
Recap: ProQR Therapeutics Q1 Earnings
May 16, 2023 | finance.yahoo.com
ProQR Announces First Quarter 2023 Operating and Financial Results
May 9, 2023 | finance.yahoo.com
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
April 20, 2023 | finance.yahoo.com
ProQR Announces Upcoming Investor Conferences in April and May
April 18, 2023 | finance.yahoo.com
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
March 31, 2023 | benzinga.com
ProQR Therapeutics Stock (NASDAQ:PRQR), Earnings Estimates, EPS, and Revenue
See More Headlines
Receive PRQR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRQR Company Calendar

Last Earnings
8/03/2023
Today
10/04/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRQR
CUSIP
N/A
CIK
1612940
Web
www.proqr.com
Phone
(188) 166-7000
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.88
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.80
Forecasted Upside/Downside
+169.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,600,000.00
Net Margins
-1,427.27%
Pretax Margin
-1,433.16%
Return on Equity
-86.23%
Return on Assets
-34.38%

Debt

Debt-to-Equity Ratio
0.07
Current Ratio
5.71
Quick Ratio
5.71

Sales & Book Value

Annual Sales
$4.25 million
Price / Sales
27.38
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.85 per share
Price / Book
1.69

Miscellaneous

Outstanding Shares
80,820,000
Free Float
74,028,000
Market Cap
$116.38 million
Optionable
Optionable
Beta
0.09
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Domenico Valerio Ph.D. (Age 67)
    Founder & Independent Chairman of Supervisory Board
    Comp: $78.97k
  • Mr. Daniel Anton de Boer (Age 40)
    Founder, CEO & Member of Management Board
    Comp: $1.41M
  • Mr. Rene K. Beukema (Age 59)
    Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board
    Comp: $313.76k
  • Dr. Gerard Platenburg (Age 59)
    Co-Founder & Chief Scientific Officer
  • Mr. Jurriaan Dekkers (Age 47)
    Chief Financial Officer
  • Ms. Sheila Sponselee (Age 39)
    VP & Head of People and Operations
  • Ms. Sarah Cue Kiely
    VP of Investor Relations & Corp. Communications
  • Ms. Sandra van der Kolk
    Jr. Financial Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













PRQR Stock - Frequently Asked Questions

Should I buy or sell ProQR Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRQR shares.
View PRQR analyst ratings or view top-rated stocks.

What is ProQR Therapeutics' stock price forecast for 2023?

6 brokerages have issued 12 month price objectives for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $1.80 to $5.00. On average, they predict the company's share price to reach $3.88 in the next year. This suggests a possible upside of 169.7% from the stock's current price.
View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts.

How have PRQR shares performed in 2023?

ProQR Therapeutics' stock was trading at $3.70 at the beginning of the year. Since then, PRQR shares have decreased by 61.1% and is now trading at $1.44.
View the best growth stocks for 2023 here.

When is ProQR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our PRQR earnings forecast.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) issued its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. The biopharmaceutical company earned $1.31 million during the quarter, compared to analysts' expectations of $2.77 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 86.23% and a negative net margin of 1,427.27%.

What ETF holds ProQR Therapeutics' stock ?

Morningstar US Small Growth holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

How do I buy shares of ProQR Therapeutics?

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $1.44.

How much money does ProQR Therapeutics make?

ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $116.38 million and generates $4.25 million in revenue each year. The biopharmaceutical company earns $-68,600,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

The company employs 130 workers across the globe.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.

This page (NASDAQ:PRQR) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -